Relief Therapeutics
About Relief Therapeutics
Relief Therapeutics aims to become a key player in the biotechnology and pharmaceutical industry.We will provide patients with therapeutic relief from diseases for which high needs persist.
We strongly believe that only by effectively treating patients will our investors realize significant return on investment.
Our areas of interest cover a broad range of indications from niche (orphan indications) up to larger markets.
Our experimental drugs are primarily of natural origin and have been already tested or used safely in the clinical setting thereby minimizing risks and maximizing efficacious potential.
Relief focuses on late stage clinical assets and strives to reduce development times and costs to quickly reach high quality decisive results.
YEAR FOUNDED:
1956
LEADERSHIP:
CEO: Raffaele Petrone
CFO: Tim Snyder
COO: Gael Hedou
CSO: Yves Sagot
Chief Business Officer: Michel Dreano
Chief Development Officer: Dorian Bevec
168 articles with Relief Therapeutics
-
Relief Therapeutics Files Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
5/11/2022
RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 2 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission.
-
Skip to main content Enable accessibility for visually impaired Open the accessibility menu Open the Accessible Navigation Menu Accessibility Widget Relief Therapeutics to Participate in Industry and Investor Conferences in May 2022
5/9/2022
RELIEF THERAPEUTICS Holding SA announced participation in the following industry and investor conferences in May.
-
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Genetic Metabolic Dieticians International Conference
5/6/2022
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA, announced the presentation of data evaluating the bioavailability, bioequivalence and taste attributes of ACER-001 compared to sodium phenylbutyrate powder during poster sessions at the recent Genetic Metabolic Dieticians International Conference on May 5, 2022, in Las Vegas, Nevada.
-
Relief Therapeutics Announces Notice of Annual General Meeting of RELIEF THERAPEUTICS Holding SA
5/6/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, gives notice of the Annual General Meeting of shareholders to be held on May 31, 2022.
-
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Receives Notice of Allowance of Key U.S. Patent Application Covering PKU GOLIKE(R)
4/27/2022
RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has received a Notice of Allowance from the U.S. Patent and Trademark Office for Patent Application No. 15/303,121 entitled, "Modified Release Orally Administered Amino Acid Formulations.".
-
Relief Therapeutics Appoints Drew Cronin-Fine as Executive Director, Head of U.S. Marketing
4/26/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced the appointment, effective May 3, 2022, of Drew Cronin-Fine as Executive Director, Head of U.S. Marketing.
-
Relief Reports that its U.S. Collaboration Partner has Filed a New Breakthrough Therapy Designation Request for Aviptadil
4/22/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc.,
-
Acer Therapeutics and Relief Therapeutics Announce Presentation of ACER-001 Data at the Society for Inherited Metabolic Disorders Annual Meeting
4/12/2022
Acer Therapeutics Inc. and its collaboration partner, Relief Therapeutics Holding SA, announced the presentation of data evaluating the bioavailability, bioequivalence and taste attributes of taste-masked sodium phenylbutyrate compared to sodium phenylbutyrate ) powder during poster sessions at the recent Society for Inherited Metabolic Disorders Annual Meeting on April 10-13, 2022 in Orlando, Florida.
-
Relief Therapeutics Announces that its Subsidiary was Issued a Swiss Patent Entitled 'Vasoactive Intestinal Peptide (VIP) for the Use in the Treatment of Drug-induced Pneumonitis'
4/1/2022
RELIEF THERAPEUTICS Holding SA reported that the Swiss Patent Office IPI has issued a patent WO2020/225246 entitled, "Vasoactive Intestinal Peptide for the Use in the Treatment of Drug-induced Pneumonitis," to Relief's subsidiary, AdVita Lifescience GmbH.
-
Relief Reports that its U.S. Collaboration Partner has Announced that the I-SPY COVID Trial Suggests No Clinical Benefit with Addition of Nebulized Aviptadil in Critically Ill Patients with COVID-19
4/1/2022
RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc., and Quantum Leap Healthcare Collaborative, have announced that the nebulized form of aviptadil being used in the I-SPY COVID Trial of critical COVID-19 patients has been stopped.
-
Relief Reports Full-Year 2021 Results and Provides Corporate Update
3/31/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, reported its results for the full-year ended December 31, 2021 and provided a corporate update.
-
Relief Therapeutics Reports In Vivo Data Indicating Prolonged Release of Amino Acids Using its Physiomimic(TM) Technology May Have Benefits for the Treatment of PKU
3/28/2022
RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported data published in the peer reviewed International Journal of Molecular Sciences, indicating that prolonged release of amino acids formulated with APR's PhysiomimicTM Technology may have benefits for the dietary management of phenylketonuria.
-
Relief Receives Trademark Registration for RLF-100(R) From the U.S. Patent and Trademark Office
3/24/2022
RELIEF THERAPEUTICS Holding SA announced that, on March 22, 2022, it received the certificate of registration for a trademark for RLF-100, from the United States Patent and Trademark Office.
-
Relief Therapeutics Appoints Christopher Wick as Senior Director, Head of U.S. Sales
3/21/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced the appointment of Christopher Wick to the newly created position of Senior Director, Head of U.S. Sales.
-
Relief Therapeutics Files Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission
3/21/2022
RELIEF THERAPEUTICS Holding SA, announced that it has filed Amendment No. 1 to its Registration Statement on Form 20-F with the U.S. Securities and Exchange Commission.
-
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research, Reports Final Data from Its Clinical Trial of Novel Nasal Spray, Sentinox, in SARS-CoV-2 Infected Patients
3/17/2022
RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, reported final data from its clinical trial of nasal spray, Sentinox, in SARS-CoV-2 infected patients.
-
Relief Therapeutics' Wholly Owned Subsidiary, APR Applied Pharma Research Signs an Agreement To Acquire Rights to Commercialize a Novel Dosage Form for the Treatment of PKU
3/15/2022
RELIEF THERAPEUTICS Holding SA announced that its wholly owned subsidiary, APR Applied Pharma Research SA, has signed a binding term sheet with Meta Healthcare Ltd. to acquire the worldwide commercialization rights, except in the United Kingdom and Ireland, for a novel dosage form of a prescription drug already approved by the U.S. Food and Drug Administration and intended for the treatment of patients with phenylketonuria.
-
Relief Reports that its U.S. Collaboration Partner has Announced that the U.S. National Institutes of Health Study of Aviptadil in Critical COVID-19 is Cleared to Complete Full Enrollment
2/16/2022
RELIEF THERAPEUTICS Holding SA reported that the parent company, NRx Pharmaceuticals, Inc., of its collaboration partner with respect to aviptadil, NeuroRx, Inc., has announced results of a review conducted by the Therapeutics and Prevention Data Safety and Monitoring Board of the National Institute of Allergy and Infectious Diseases of the National Institutes of Health on February 14, 2022.
-
Relief Files Trademark Application for RLF-100 With the U.S. Patent and Trademark Office
2/8/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced that it is has filed for a trademark for RLF-100TM with the United States Patent and Trademark Office.
-
Relief Therapeutics Expands Its Board of Directors with the Appointment of Michelle Lock
2/2/2022
RELIEF THERAPEUTICS Holding SA, a biopharmaceutical company seeking to provide patients therapeutic relief from serious diseases with high unmet need, announced that, as approved and reported after its January 28, 2022 extraordinary general meeting, Michelle Lock, Chief Operating Officer of Covis Pharma Group, has been appointed to the company's Board of Directors.